PR Newswire Asia's news > Biotechnology

 < Previous page   |   Detail   |   Print    Next page > 
     
Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
2026-08-10T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Dx&Vx Signs Two Material Transfer Agreements in Latin America Within Two Months -- "Technology Validated Across Both Public and Private Sectors"
2026-08-10T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
2026-08-10T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
2026 Global Health Summit Opens in Hong Kong -- Global Healthcare Leaders Convene: Bringing Breakthroughs to Patients
2026-08-10T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections
2026-08-10T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
2026-08-08T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Telix to Host R&D Day in New York City on September 22, 2026
2026-08-06T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
NYSE Content Update: Expedition Therapeutics Secures $115 Million Series B
2026-08-05T    Banking/Financial Service   Biotechnology   Computer/Electronics 
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
2026-08-05T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Alteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product
2026-08-05T    Biotechnology   Health Care/Hospital 
 < Previous page    Next page >

 

88iv | Home |  Login
Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer
Copyright (C) 2026
Suntek Computer Systems Limited.
All rights reserved